Citilin® [amp]

Korea United Pharm [ Pharma 3 ]

MIMS Class : Nootropics & Neurotonics

See related Citilin amp information

Contents Citicoline
Indications Treatment of stupor caused by head trauma, cerebral surgery, acute stage
of cerebral infarction and hemiplegia after cerebral apoplexy. Treatment
of Parkinson's disease in combination w/ anticholinergics.

Concomitant therapy w/ antiproteolytic agents for pancreatitis.

Dosage Stupor Caused by Head Trauma and Cerebral Surgery: The usual
adult dosage of citicoline is 100-500 mg once or twice daily given in
divided IV or IM administration.

Stupor Caused by Acute Stage Infarction: Usual adult dosage of

citicoline is 1 g once daily for 2 consecutive weeks.

Hemiplegia After Cerebral Apoplexy: Citicoline 1 g or 250 mg is

administered IV once a day for 4 weeks> If symptoms are improved,
administer IV for 4 more weeks.

Parkinson's Disease: The usual daily dose is 500 mg IV once daily in

concomitant therapy with anticholinergic agent. After concomitant
therapy with anticholinergic agent for 3-4 weeks, citicoline should be
discontinued and be considered. Dose of anticholinergic agent may be
increased or citicoline 250-500 mg may be administered concomitantly
once daily, every 2-3 weeks unless levodopa can be used. Administration
of citicoline should be stopped, provided that after administration of
citicoline 500 mg plus anticholinergic agent everyday for 2 weeks,
diseases are not improved. It is advisable to avoid concomitant
administration with levodopa since combination may cause impairment
of myotonia.

Pancreatitis: Under concomitant therapy with antiproteolytic agents,

citicoline 1 g is administered IV once a day for 2 consecutive weeks.

Or as prescribed by the physician.

Contraindications Patients with parasympathetic hypertonia.
Special Precautions In case of stupor caused by acute or severe or progressive head trauma or
 cerebral surgery, it should be given in concomitant with depressant and
hypothermic agent.

Use in pregnancy & lactation: Since it has not been established

whether citicoline may adversely affect pregnant women, citicoline
should not be used in pregnant women or women of childbearing
potential unless the benefit of treatment is considered to outweigh the
risk.

Use in children: It has not been established whether citicoline may

adversely affect children.

Use in elderly: Use in elderly should be taken with caution considering

manifestation of adverse effects.
Adverse Drug Shock: Rarely, shock may occur. It should be sufficiently observed if
Reactions hypotension, compression of chest and dyspnea have developed.
Administration should be discontinued and/or appropriate therapy be
instituted.

Hypersensitivity: Eruption may appear occasionaly, in this case

administration should be discontinued.

Psychoneurologic: Headache, vertigo, excitation can develop.

Gastrointestinal: Occasionally, nausea and rarely anorexia may occur.

Hepatic: Abnormalities in hepatic test may occur.

Others: Sometimes, burning sensation, temporary change in blood

pressure and malaise may appear.
Click to view ADR Monitoring Website
Drug Interactions In combination with levodopa, Citilin can increase effects of levodopa.
View more drug interactions for Citilin
Storage Store at temperatures not exceeding 30°C.
Mechanism of Pharmacokinetics: Citicoline is a water-soluble compound with >80%
Action bioavailability. Pharmacokinetic studies on healthy adults show oral
doses of citicoline are rapidly absorbed, with <1% excreted in feces.
Plasma levels peak in a biphasic manner, at 1 hr after ingestion followed
by a second larger peak at 24 hrs post-dosing. Citicoline is metabolized
in the gut well and liver. The byproducts of exogenous citicoline formed
by hydrolysis in the intestinal wall are choline and cytidine. Following
absorption, choline and cytidine are dispersed throughout the body, enter
systemic circulation for utilization in various biosynthetic pathways and
cross the blood-brain barrier for resynthesis into citicoline in the brain.
MIMS Class Nootropics & Neurotonics
ATC Classification N06BX06 - Citicoline ; Belongs to the class of other psychostimulants
and nootropics.
Poison Schedule Rx
Presentation/Packing Amp (clear, colorless solution in colorless amp) 500 mg/ 2mL x 10's. 1
g/4 mL (clear, colorless solution in colorless amp) x 10's

flunarizine

MIMS Class : Antimigraine Preparations

See available brands of flunarizine

See related flunarizine information

Indication & Oral

Dosage Prophylaxis of migraine, Prophylaxis of vertigo and vestibular disorders,
Prophylaxis of peripheral and cerebrovascular disorders
Adult: 5-10 mg daily at bedtime.

Administration May be taken with or without food.

Contraindications Pregnancy, lactation, GI or urinary tract obstruction, acute porphyrias.

Special Precautions Driving or operating machinery, epilepsy, elderly, CVS disease, glaucoma.

Adverse Drug Drowsiness. Rarely wt gain, headache, depression, gastric pain, dry mouth,
Reactions insomnia, extrapyramidal reactions, galactorrhoea.

Drug Interactions Plasma levels reduced by phenytoin, carbamazepine, valproic acid.

Click to view more Drug Interactions
Storage Oral: Store below 25°C.

Mechanism of Flunarizine has H1-receptor blocking action and calcium-channel blocking effect. It
Action has also been used as an adjunct epileptic therapy for patients refractory to
standard treatment regimens.
Absorption: Absorbed well from the GI tract (oral).
Distribution: Highly lipophilic. Protein-binding: >90%.
Metabolism: Extensive.
Excretion: Via bile (as metabolites); 18 days (elimination half-life).

MIMS Class Antimigraine Preparations

ATC Classification N07CA03 - flunarizine; Belongs to the class of preparations used in the treatment
of vertigo.

piracetam

MIMS Class : Nootropics & Neurotonics

See available brands of piracetam

See related piracetam information

Indication Listed in Dosage.

Dosage Adult: PO Adjunct in treatment of cortical myoclonus 7.2 g/day in 2-3 divided
doses, increase if needed. Max: 20 g/day. Cognitive enhancer 2.4 g/day in 2-3
divided doses. Severe: Up to 4.8 g/day. IV/IM Cognitive enhancer 1-2 g 3
times/day.
Click to view Dosage by Indications

Administration Should be taken with food. (Take before meals.)

Contraindications Hepatic and severe renal impairment. Cerebral haemorrhage. Pregnancy and
lactation.

Special Precautions Avoid abrupt withdrawal. Impaired renal function. Cardiac disorders. Haemostatic
 disorders. Patients who have recently undergone major surgery. Elderly.

Adverse Drug Hyperkinesia, nervousness, depression, diarrhoea, rashes. CNS stimulation, sleep
Reactions disturbances, dizziness, excitement, insomnia, somnolence, wt gain.

Drug Interactions May increase prothrombin time in patients who are on warfarin.
Click to view more Drug Interactions

Mechanism of For details of the mechanism of action, pharmacology and pharmacokinetics and
Action toxicology ... click to view

MIMS Class Nootropics & Neurotonics

ATC Classification N06BX03 - piracetam; Belongs to the class of other agents used as CNS stimulant.

Diabetes Therapy

Insulin product SciLin receives health care

registration in the Philippines
Published in Obesity and Diabetes Week, March 21st, 2005

The directors of SciGen Limited announced that the company has received health care registration for its
insulin product SciLin in the Philippines.

Preparations are well underway for the sales launch of SciLin in the Philippines to occur as soon
as possible.

SciLin is a second-generation recombinant human insulin that SciGen has the exclusive rights to
market in the Asia Pacific Region.

SciLin is currently registered and sold by SciGen or its partners in India, Vietnam, and Pakistan.

This article was prepared by Obesity & Diabetes Week editors from staff and other reports.
Copyright 2005, Obesity & Diabetes...